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Abstract
Background: The protein of Niemann-pick type C1 gene (NPC1) is known to facilitate the egress of cholesterol and
other lipids from late endosomes and lysosomes to other cellular compartments. This study aims to investigate
whether the genetic variation in NPC1 is associated with risk of coronary heart disease (CHD) and to detect
whether NPC1 might interact with smoking on the risk of CHD.
Methods: We performed a case-control study, including 873 patients with coronary heart disease (CHD) and 864
subjects without CHD as control. Polymorphisms of NPC1 gene were genotyped by polymerase chain reaction
(PCR) -restriction fragment length polymorphism (RFLP).
Results: A tag-SNP rs1805081 (+644A > G) in NPC1 was identified. The G allele of the +644 locus showed reduced
risk of CHD than wild-type genotype in Chinese population (recessive model GG vs. AG+AA: odds ratio [OR] 0.647,
95% CI 0.428 to 0.980, P = 0.039; additive model GG vs. AG vs. AA: OR 0.847, 95% CI 0.718 to 0.998, P = 0.0471).
Moreover in smokers, the G-allele carriers had reduced risk of CHD compared with A-allele carries (OR 0.552, 95%
CI 0.311 to 0.979, P = 0.0421).
Conclusions: The results of the present study suggest that NPC1 variants seem to be contributors to coronary
heart disease occurrence in Chinese population. Moreover, in smokers, NPC1 variants seem to confer protection to
coronary heart disease.
Background
Coronary heart disease is one of the leading causes of
morbidity and mortality in China. It is still a big chal-
lenge for medical society to elucidate the pathogenesis
and to identify the subjects at risk. Coronary heart dis-
ease develops dependent of genetic predisposition and
the accumulation of risk factors that lead to a wide
array of molecular and cellular abnormalities within the
vessel wall. It is well established that the formation of
foam cell or atherosclerotic plaque is the hallmark event
leading to coronary heart disease, Foam cells in athero-
sclerotic lesions derive from macrophages and vascular
smooth muscle cells (VSMCs)[1]. Free cholesterol (FC)
accumulation in lesional foam cells has been well docu-
mented in advanced atherosclerosis, and studies with
cultured macrophages have shown that acceleration of
FC accumulation in lesional macrophages in mice leads
to increased lesional macrophage apoptosis[2-4]. Deliv-
e r yo ff r e ec h o l e s t e r o lf r o mt h ee n d o c y t i cp a t h w a yt o
the plasma membrane and endoplasmatic reticulum
(ER) requires the coordinated actions of the late endoso-
mal Niemann-pick type C1 protein (NPC1). NPC1 pro-
tein inactivation results in lipid accumulation in late
endosomes and lysosomes, leading to a defect of ATP
binding cassette protein A1 (Abca1)-mediated lipid
efflux to apolipoprotein A-I (apoA-I) in macrophages
and fibroblasts[5].
NPC1 protein is a membrane protein localized in the
late endosomes and regulates intracellular cholesterol
trafficking [6]. Loss of NPC1 function leads to defective
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any medium, provided the original work is properly cited.suppression of sterol regulatory element binding protein
(SREBP)-dependent gene expression and failure to
appropriately activate liver X receptor-mediated path-
ways, ultimately resulting in intracellular cholesterol
accumulation in macrophages and fibroblasts[7,8].
Niemann-Pick type C disease is an autosomal, recessive
disorder characterized by intracellular accumulations of
cholesterol and other lipids throughout the body.
Affected individuals exhibit progressive neurodegenera-
tion, leading to death in childhood, adolescence, or early
adulthood. The underlying gene, NPC1 responsible for
95% of Niemann-Pick type C disease, encodes a multi-
spanning membrane protein containing a sterol-sensing
domain that is required for the egress of cholesterol
from late endosomes [9].
Cigarette smoking is a recognized risk factor for cardi-
ovascular diseases and has been implicated in the patho-
genesis of atherosclerosis[10]. Aryl hydrocarbons (AHs)
such as 2,3,7,8-tetrachlorodibenzop-dioxin (TCDD) and
polycyclic AHs (PAHs), which are especially found in
cigarette smoking, had been recently demonstrated to
promote the transformation of macrophages to foam
cells in the atherosclerosis process [11]. Benzo(a)pyrene
(BP)[12], a prototypical PAH, has thus been shown to
accelerate atherosclerotic plaque development in apoli-
poprotein-E knock-out mice, via promoting a local
inflammatory response, and inducing DNA damage in
human blood vessels. In TCDD- and BP-exposed
macrophages the NPC1 expression decreased at both
mRNA and protein levels.
NPC1-deficient cells exhibit a defect in the intracellu-
lar trafficking of low-density lipoprotein-derived choles-
terol, leading to cholesterol accumulation in late
endosomes and lysosomes and defects in endoplasmic
reticulum-initiated cholesterol regulatory events[13].
Some scientists [14,15] have reported that mice carrying
a naturally occurring null mutation of NPC1 have a
defect in apoA-1-mediated cholesterol efflux from
macrophages. This underlines the relationships between
NPC1, cholesterol homeostasis, and lipid accumulation
and cigareete smoking. The aim of this study was to
look at the association and linkage between the NPC1
gene polymorphism and coronary heart disease in a Chi-
nese population. In addition, the relationship of the
NPC1 gene polymorphism with cigarette smoking was
assessed.
Methods
Study sample
The study was approved by the institutional review
board of cardiovascular institute, and the participating
hospitals. All subjects who participated in the study pro-
v i d e dt h e i rw r i t t e ni n f o r m e dc o n s e n ta n dw e r es e l f -
reported as Han nationality. The subjects of the study
consisted of 873 CHD patients and consisted of 864
control subjects without CHD. The 873 case subjects
were recruited from FuWai Hospital from December
2004 to December 2006. Inclusion criteria was >70%
narrowing of the lumina of at least 1 major coronary
artery according to their coronary angiography (CAG)
results. A detailed history of angina or MI was obtained.
Patients with MI were judged by typical ECG change
(Minnesota Code 1.1 or 1.2 in ECG) and by changes in
serum enzymes (troponin T, troponin I, creatine kinase-
MB, aspartate aminotransferase, and glutamic pyruvic
transaminase)[16].
The 864 control subjects were recruited from 24 com-
munities in China, whose major coronary arteries had
no more than 20% stenosis and who did not have any
vascular disease.
Biological variable determination and clinical data
collection
Blood samples were collected after a 12-hour overnight
fast before cardiovascular procedures. In subjects with an
acute event, the drawing of blood was delayed for at least
6 weeks. The plasma and cell buffet coat were kept at
-70°C. Genomic DNA was extracted, and biological vari-
ables were determined within 3 months. A complete clin-
ical history was obtained from all subjects. In addition to
family history of hypertension[17], MI, and diabetes mel-
litus (DM), the following vascular risk factors were also
recorded: history of vascular disease, cigarette smoking
[18], body mass index (BMI), systolic blood pressure
(SBP), diastolic blood pressure (DBP), blood glucose,
high density lipoprotein cholesterol (HDL-C), low density
lipoprotein cholesterol (LDL-C), total plasma cholesterol
(TC), and triglycerides (TG). Hypertension was defined
as a mean of 3 independent measures of blood pressure
≥140/90 mm Hg or the use of antihypertensive drugs.
DM was diagnosed when the subject had a fasting glu-
cose level ≥7.0 mmol/L, ≥11.1 mmol/L at 2 hours after
oral glucose challenge, or both[19].
SNP selection
SNPs in NPC1 gene were retrieved from HapMap data-
base for CHB (Chinese Han in Beijing) sample (release
N o .2 4 / p h a s e I IN o v 0 8 ,o nN C B IB 3 6a s s e m b l y ) .W e
searched across a 47-kb region spanning NPC1 gene
from 1 kb upstream of the 5′-flanking region to 0.5 kb
downstream of the 3′-flanking region. The percent cov-
erage of HapMap variants is subjected to a minor allele
frequency (MAF) threshold of 0.05 and an r
2 >0 . 8
threshold with pair-wise tagging, using Haploview soft-
ware (3.31 version). After excluded those SNPs in
introns, we identified one important SNP rs1805081
(+644A > G) with a MAF of 0.374, which causes a mis-
sense mutation from His215 to Arg in NPC1 protein.
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Genomic DNA was isolated from peripheral blood leu-
kocytes by the FlexiGene DNA Kit (Qiagen, Hilden,
Germany). Genotyping was carried out by PCR-RFLP
analysis. Primers were designed with Oligo 6 software as
following: 5′-GGGTTGCCTTGGTATGTG-3′ and 5′-
GATCGTCCAGGGAGCAG-3′. The reaction mixture
was subjected to denaturation at 95°C for 5 min, fol-
lowed by 34 cycles at 94°C for 20 sec, 60°C for 30 sec,
72°C for 35 sec, then by a final extension at 72°C for
5 min. The resultant polymerase chain reaction (PCR)
products were digested with NcoI (New England
Biolabs, Beverly, Mass), which yielded 2 DNA fragments
of 269 and 143 bp for the A allele on 3.5% agarose
gel and only one 412 bp band for the G allele. Reprodu-
cibility of genotyping was confirmed by bidirectional
sequencing in 50 randomly selected samples, and the
reproducibility was 100%.
Statistical Analysis
Quantitative variables, including age, body mass index,
SBP and DBP, glucose, HDL-C, LDL-C, and TC, were
compared with the 1-way ANOVA test. A c
2 test was
used to test for qualitative variables, genotype/allele fre-
quencies, and Hardy-Weinberg equilibrium of the poly-
morphisms. ORs and 95% CIs were computed with the
use of binary logistic regression analyses. Adjusted ORs
were stratified by age, sex, body mass index, hyperten-
sion history, cigarette smoking, and Diabetes mellitus
history. Gene-envirionment interaction were calculated
by binary logistic regression analyses and software for
calculating measures of biological interaction[20]. A
2-tailed probability value of ≤0.05 was considered sig-
nificant. Analyses were performed with SAS9.1 for
Windows (Microsoft Corp, Redmond, Wash).
Results
G allele of tag SNP rs1805081 was associated with risk of
CHD
Clinical characteristics of the subjects in the present
study are shown in Table 1. In this group, significantly
higher ratio of men, higher levels of TG, lower level of
HDL-C, higher cigarette smoking rate and higher inci-
dence of DM were found in cases than in controls (all
P < 0.01). The distribution of the genotypes of tag SNP
rs1805081 is shown in Tables 2. All genotypes conformed
to Hardy-Weinberg equilibrium expectation in this
group. The genotype frequency of the rs1805081 from
the HapMap data was similar to ours. We analyzed the
association of rs1805081 with CHD using both a domi-
nant model and an additive model. The genotype fre-
quencies of G allele homozygote and heterozygote were
significantly lower in patients with CHD than in control
subjects, and the protective allelic frequencies were also
lower in CHD patients than in control subjects (Table 2).
The association remained after adjustment for by age,
sex, body mass index, hypertension history, cigarette
smoking, Diabetes mellitus history with binary logistic
regression analysis, supporting that G allele of tag SNP
NPC1 was a protective factor for CHD. As shown in
Table 3, in this population, the odds ratio [OR] was 0.647
(95% confidence interval [CI] 0.428 to 0.980, P = 0.039)
under a recessive model (GG vs. AA+AG) and 0.847
(95% confidence interval [CI] 0.718 to 0.998, P = 0.047)
under an additive model (GG vs. AG vs. AA).
NPC1 ploymorphism interact with smoking on coronary
atherosclerosis
The odds ratio of smoking alone on CHD risk was 2.42
(95% CI 1.959 to 2.988, P < 0.0001). To determine whether
smoking influenced the effects of gene load on coronary
heart disease. We analyzed the association of +644A/G
with CHD by two group, nonsmoking and smoking.
Among smokers, in recessive model (GG vs. AA+AG) and
additive model (GG vs. AG vs. AA) the genotype frequen-
cies of G allele homozygote and heterozygote were lower
in CHD patients than in control subjects (table 4). The
ORs were adjusted by age, sex, body mass index, hyperten-
sion history, Diabetes mellitus history.
The interaction effect between +644A/G and cigar-
ette smoking were calculated in two most widely used
Table 1 Clinical Characteristics of the Population
Characteristics CHD Controls
N 873 864
age, year** 51 (8.14) 53 (8.39)
Men,n (%)* 734 (84.0) 612 (70.8)
Body mass index, kg/m
2 25.57(3.20) 24.95(9.37)
HDL-C, mmol/L** 1.18 (0.37) 1.35 (0.35)
LDL-C, mmol/L** 2.37 (0.78) 2.75 (0.85)
TC, mmol/L** 4.47 (1.05) 5.03 (1.10)
TG, mmol/L** 1.34 (1.26) 1.12 (1.43)
Cigarette smoking, n (%)** 582 (66.67) 351 (40.91)
Hypertension history, n (%) 431 (49.39) 412 (47.74)
Diabetes mellitus history, n (%)** 183 (20.96) 67 (7.75)
Clinical characteristics of age, Body mass index, LDL-C, HDL-C, TC and TG
values are given as mean (SD); and other values as number of individuals.
*P < 0.05, **P < 0.01 vs. control.
Table 2 The distribution of the genotypes of rs1805081
in NPC1
Genotype,n(%) Allele, n(%)
Groups AA AG GG A G
Controls
(n = 864)
479
(55.44)
316
(36.57)
69
(7.99)
1274
(73.73)
454
(26.27)
Cases
(n = 873)
512
(58.65)
314
(35.79)
47
(5.38)
1338
(76.63)
408
(23.37)
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additive interaction mode. In multiplicative interaction
mode, there was a significant interaction between
NPC1 genotype and cigarette smoking on risk for
CHD (P for interaction = 0.0001). Using four-by-two
table to estimate additive interaction between +644A/
G and cigarette smoking, we found no interaction
between NPC1 genotype and cigarette smoking on risk
for CHD (Table 5).
Discussion
The present study provides evidence that +644A > G, a
common variant of NPC1, was associated with a
decreased risk of CHD patients in recessive and additive
model. Moreover, in smokers, carriers of NPC1 GG had
a decrease risk of coronary heart disease as compared
with those carrying AA and AG. Multivariate adjust-
ments support that the effects are independent of com-
mon traditional cardiovascular risk factors, including
age, sex, body mass index, hypertension history, Dia-
betes mellitus history. Hypercholesterolemia is tradi-
tional cardiovascular risk factor of CHD. However, in
this study the CHD patients almost took cholesterol-
lowering drugs to control cholesterol levels. Therefore
compared with control, LDL-C and TC were significant
lower and HDL-C was significant higher in CHD
patients (P < 0.01). Because of cholesterol-lowering
drugs influences, in the logistic regression model the
results did not adjusted by the classical risk factor LDL-
C, HDL-C, TG and TC.
A connection between the NPC1 and atherosclerosis
has been established in several studies. Deletion of
NPC1 in BM-derived cells accelerated atherosclerosis by
impairing cholesterol efflux and promoting cellular oxi-
dative stress. Jessie R. Zhang et al. disrupted NPC1
expression in macrophages of Ldlr
-/- mice and demon-
strated that absence of NPC1 expression was proathero-
genic in vivo[21]. Macrophages from mice with NPC1
heterozygous mutation have a selective defect in choles-
terol trafficking to the ER and are protected from cho-
lesterol-induced apoptosis [22]. Our study indicated that
the variant allele G at position +644 in NPC1 is asso-
ciated with decreased risk of CHD. The NPC1 choles-
terol trafficking pathway could have an impact on the
progress of atherosclerosis by above mechanisms.
Furthormore, rs1805081 has been found to be associated
with obesity[23] and Alzheimer’s[24] while studies in
mice suggest that the G allele is protective here and
might be associated with NPC1 activity. Moreover, the
NPC1 cholesterol trafficking pathway regulates liver
X receptor-dependent cholesterol efflux in vivo, alleviat-
ing cholesterol-induced oxidative stress and serving an
atheroprotective role. The NPC1
-/- chimeric mice exhib-
ited increased atherosclerotic lesion formation despite
lower cholesterol and TG levels in the VLDL and LDL
fractions. NPC1 heterozygosity was associated with resis-
tance to lesional necrosis and lesional macrophage
apoptosis. More recently, Welch et al. [25] reported that
Table 3 Association of rs1805081 in NPC1 Gene with CHD
in the Population
Models Crude ORs(95%
CI)
Adjusted ORs
(95% CI)
Adjusted P
Value
GG vs. AG
+AA
0.656(0.447 to
0.962)
0.647(0.428 to
0.980)
0.0399
GG vs. AG vs.
AA
0.859(0.738 to
1.001)
0.847(0.718 to
0.998)
0.0471
GG+AG vs.
AA
0.877(0.725 to
1.061)
0.860(0.701 to
1.055)
0.1489
ORs and 95% CIs were computed with the use of binary logistic regression
analyses. Adjusted ORs were stratified by age, sex, body mass index,
hypertension history, cigarette smoking, and Diabetes mellitus history.
Table 4 Association of rs1805081 in NPC1 Gene with CHD classified by smoking
non-smoking smoking
Models ORs(95% CI) P Value ORs(95% CI) P Value
GG vs. AG+AA Crude 0.773(0.441 to 1.357) 0.3703 0.606(0.351 to 1.047) 0.0727
Adjusted 0.766(0.423 to 1.386) 0.3537 0.552(0.311 to 0.979) 0.0421
GG vs. AG vs. AA Crude 0.954(0.759 to 1.198) 0.6839 0.810(0.652 to 1.006) 0.0571
Adjusted 0.909(0.714 to 1.158) 0.441 0.778(0.620 to 0.976) 0.0301
GG+AG vs. AA Crude 0.994(0.744 to 1.328) 0.9672 0.817(0.625 to 1.068) 0.1391
Adjusted 0.846(0.622 to 1.151) 0.2868 0.804(0.607 to 1.065) 0.1277
ORs and 95% CIs were computed with the use of binary logistic regression analyses. Adjusted ORs were stratified by age, sex, body mass index, hypertension
history, cigarette smoking, and Diabetes mellitus history.
Table 5 The additive interaction of rs1805081 in NPC1
Gene with CHD in the Population
Modle
measure(95% CI) recessive additive
RERI -0.240 (-0.913 to 0.433) -0.802 (-1.784 to 0.180)
AP -0.128 (-0.493 to 0.237) -0.626 (-1.662 to 0.410)
SI 0.786 (0.417 to 1.481) 0.260 (0.018 to 3.687)
RERI(relative excess risk due to interaction), AP (attributable proportion due to
interaction) and SI (synergy indes) with CI (confidence intervals). Lack of
interaction is reflected by RERI = AP = 0 and SI = 1.
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-/- mutation into the Apoe
-/-
background predisposed to increased lesion formation
and atherothrombosis.
Smoking is known to raise serum lipid levels, and is
considered as one of the major risk factors for the
development of atherosclerosis disease. In the present
study, we showed that within non-smokers, the coronary
heart disease risk did not differ between NPC1 geno-
types. In smokers, however, both in recessive model
(GG vs. AA+AG) and additive model (GG vs. AG vs.
AA) NPC1 G carriers showed decreased coronary heart
disease risk compared with A carriers. Furthermore in
multiplicative interaction mode, there was a significant
interaction between NPC1 +644A > G and cigarette
smoking on risk for CHD. However, the biological basis
of NPC1-smoking interaction on lipid concentration and
CHD risk is still unclear. Smoking might lower NPC1
transcription, by somehow disrupting the binding of
transcription factors, therefore, leading to intracellular
cholesterol accumulation. Normand Podechard[26]
recently found that human macrophages exposed to
environmental aryl hydrocarbons and Aryl hydrocarbons
(AHs) was found to decrease expression of NPC1 at
both mRNA and protein levels. Moreover 2,3,7,8-tetra-
chlorodibenzop-dioxin (TCDD) and polycyclic AHs
(PAHs), which are especially found in cigarette smoking,
had been recently demonstrated to promote the trans-
formation of macrophages to foam cells in the athero-
sclerosis process[11].
We also examined whether the disease-associated
alleles were related to specific vascular risk factors,
including age, sex, body mass index, hypertension his-
tory, Diabetes mellitus history. After adjusting for those
conventional cardiovascular risk factors, the association
remained significant, suggesting that the contribution of
this variant to the risk of CHD is independent of con-
ventional cardiovascular protective factors.
The strength of the present study is the large sample
size, and community-based sample. However, there are
some limitations in the present study, including that there
isn’t the second case-control study to replicate the first
study results. Moreover, a longitudinal follow-up study is
required to elucidate whether there are protective effects
of NPC1 variants on CHD in the future. In conclusion, a
genetic variant of NPC1 could contribute to predict ather-
osclerotic and suggest therapeutic strategies to promote
plaque stability. The results need to be replicated in other
nationalities and confirmed with a prospective trial. The
mechanisms need to be further explored.
Conclusions
The results of the present study suggest that NPC1
variants seem to be contributors to coronary heart dis-
ease occurrence in Chinese population. Moreover, in
smokers, NPC1 variants seem to confer protection to
coronary heart disease.
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